DEF: Ginkgo Bioworks Announces 2025 Annual Meeting of Shareholders, Outlines Key Proposals

Ginkgo Bioworks will hold its 2025 Annual Meeting of Shareholders virtually on June 12, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Summary

• Ginkgo Bioworks is holding its Annual Meeting of Shareholders on June 12, 2025, at 8:00 a.m. Eastern Time, as a virtual-only meeting.
• Shareholders of record as of April 17, 2025, are eligible to vote.
• The meeting will address the election of seven director nominees, ratification of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
• The Board of Directors recommends voting FOR all listed proposals.
• The proxy statement and 2024 Annual Report are available online at www.proxyvote.com.
• The company had 45,956,669 shares of Class A common stock and 9,191,867 shares of Class B common stock outstanding as of the record date.
• Each share of Class A common stock is entitled to one vote, while each share of Class B common stock is entitled to ten votes.
• The Board expects to decrease the size of the Board from nine directors to seven directors immediately following the Annual Meeting upon the completion of Dr. Hannans and Ms. Potters terms.
• The Board adopted changes to director cash compensation, to become effective as of the Annual Meeting, to more closely align director cash compensation with the median of Ginkgo's 2025 peer group.
• The Board adopted changes to director equity compensation, to become effective as of the Annual Meeting, to more closely align the grant date value of director equity compensation with the median of Ginkgo's 2025 peer group.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the company's commitment to shareholder engagement and corporate governance best practices. The negative aspects are limited to the inherent risks associated with forward-looking statements.

Positives

• The virtual format of the Annual Meeting enhances accessibility for all shareholders.
• Shareholders have multiple options for voting, including online, telephone, and mail.
• The Board is actively engaged in risk oversight through its committees.
• Ginkgo is committed to shareholder engagement through various communication channels.
• The company has a clawback policy for incentive compensation.
• The Board adopted changes to director cash compensation, to become effective as of the Annual Meeting, to more closely align director cash compensation with the median of Ginkgo's 2025 peer group.
• The Board adopted changes to director equity compensation, to become effective as of the Annual Meeting, to more closely align the grant date value of director equity compensation with the median of Ginkgo's 2025 peer group.

Negatives

• Dr. Kathy Hopinkah Hannan and Ms. Myrtle Potter are not standing for re-election to the Board of Directors at the Annual Meeting and their terms as a director will expire at the Annual Meeting.

Risks

• The document includes a Safe Harbor Statement cautioning about forward-looking statements and the risks and uncertainties described in Ginkgo's Annual Report on Form 10-K.
• The company acknowledges that actual results could differ materially from forward-looking statements due to various factors.

Future Outlook

The document outlines the business to be conducted at the 2025 Annual Meeting and provides information to shareholders to make informed decisions regarding voting on the proposals.

Management Comments

• Jason Kelly, CEO, welcomes shareholders to attend the 2025 Annual Meeting and encourages them to vote their shares.
• Karen Tepichin, General Counsel and Secretary, provides notice of the 2025 Annual Meeting.

Industry Context

This announcement is a standard corporate governance procedure for publicly traded companies, ensuring shareholders have the opportunity to participate in key decisions regarding the company's direction and management.

Comparison to Industry Standards

• The proxy statement adheres to SEC regulations and NYSE listing standards, ensuring transparency and compliance.
• The compensation practices are benchmarked against a peer group of companies in the life sciences and biotechnology industries, including 10X Genomics, Pacific Biosciences, and Twist Bioscience.
• The company's approach to shareholder engagement, including virtual meetings and multiple communication channels, aligns with best practices in corporate governance.

Management Changes

Corporate Governance

Related Party Transactions

• Octant, whose chief executive officer is Sri Kosuri, a member of the Board, is a commercial partner of Ginkgo, and Jason Kelly, Ginkgos chief executive officer, serves on Octants board of directors.
• Ginkgo received approximately $340,000 in revenue from Octant during the 2024 fiscal year pursuant to this contract.
• Dr. Shetty is married to Ginkgo Founder and employee Dr. Canton.
• In 2024, Dr. Canton received a salary of $250,000 and Founder Options, as further described in 2024 Founder Compensation Program above.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions affecting the company's governance and direction.
• Employees are impacted by the executive compensation program and the 401(k) retirement savings plan.
• The company's commitment to corporate governance and risk oversight aims to protect the interests of all stakeholders.

Next Steps

• Shareholders are encouraged to read the proxy statement and vote their shares before the Annual Meeting.
• Shareholders can participate in the virtual Annual Meeting on June 12, 2025.
• The Board will consider the voting results when evaluating the executive compensation program.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Shareholders, Board of Directors, Executive Compensation, Director Nominees, Deloitte & Touche LLP, Corporate Governance, Risk Oversight, Ginkgo Bioworks